Skip to content
GenoLensGenoLens

NAGA

Chr 22q13.2

alpha-N-acetylgalactosaminidase

Aliases:
D22S674
MANE:
ENST00000396398.8

Annotations refreshed 1 month ago.

Predicted protein structure

Clinical relevance (Genomics England PanelApp)

Diagnostic Grade (Green)

  • DDG2P

    BIALLELIC, autosomal or pseudoautosomal
  • Early onset or syndromic epilepsy

    BIALLELIC, autosomal or pseudoautosomal
  • Fetal anomalies

    BIALLELIC, autosomal or pseudoautosomal
  • Hereditary neuropathy

    BIALLELIC, autosomal or pseudoautosomal
  • Hereditary neuropathy or pain disorder

    BIALLELIC, autosomal or pseudoautosomal
  • Intellectual disability

    BIALLELIC, autosomal or pseudoautosomal
  • Likely inborn error of metabolism

    BIALLELIC, autosomal or pseudoautosomal
  • Lysosomal storage disorder

    BIALLELIC, autosomal or pseudoautosomal

+4 more panels — install the extension to see the full list inline on any page.

Disease associations (Open Targets)

  • alpha-N-acetylgalactosaminidase deficiency type 2

    0.80
  • alpha-N-acetylgalactosaminidase deficiency

    0.76
  • alpha-N-acetylgalactosaminidase deficiency type 1

    0.75
  • alpha-N-acetylgalactosaminidase deficiency type 3

    0.59
  • hereditary disease

    0.42
  • Seizure

    0.37
  • neurodegenerative disease

    0.35
  • Intellectual disability

    0.16
  • intelligence

    0.14
  • arthrogryposis multiplex congenita

    0.12

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Alpha-N-acetylgalactosaminidase

Removes terminal alpha-N-acetylgalactosamine residues from glycolipids and glycopeptides. Required for the breakdown of glycolipids

Data sources: HGNC (CC BY 4.0), AlphaFold (CC BY 4.0, Jumper et al. Nature 2021), Genomics England PanelApp (CC BY 4.0), ClinGen, Open Targets (CC0), UniProt.

Not for sole clinical decision-making. Always verify against primary sources.